Comparative Pharmacology
Head-to-head clinical analysis: DIMETANE versus PBZ SR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIMETANE versus PBZ SR.
DIMETANE vs PBZ-SR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dimetane (brompheniramine) is a first-generation alkylamine antihistamine that competitively antagonizes histamine at H1 receptor sites, preventing histamine-mediated effects such as vasodilation, increased capillary permeability, and bronchoconstriction. It also has anticholinergic and sedative properties.
Antihistamine; H1-receptor antagonist that competes with histamine for binding at H1 receptor sites, thereby preventing histamine-mediated allergic responses.
1-2 tablets (4-8 mg chlorpheniramine maleate) orally every 4-6 hours, not to exceed 12 tablets (48 mg) in 24 hours.
100-200 mg orally every 12 hours; maximum 400 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 12-15 hours in adults, necessitating twice-daily or three-times-daily dosing for continuous effect.
Terminal elimination half-life is approximately 4-6 hours in adults with normal renal function; clinically relevant dosing every 4-6 hours is recommended.
Primarily renal excretion of metabolites, with approximately 50% of a dose excreted in urine as unchanged drug and metabolites; biliary/fecal excretion is minor (< 10%).
Primarily renal excretion (80-90% as unchanged drug) via glomerular filtration and tubular secretion. Biliary/fecal excretion accounts for approximately 5-10%.
Category C
Category C
Antihistamine
Antihistamine